Skip to main content

Imaging Diagnostics in Pancreatic Cancer from the Perspective of an Oncologist

  • Chapter
  • First Online:
Imaging Diagnostics in Pancreatic Cancer

Part of the book series: Clinical Gastroenterology ((CG))

  • 369 Accesses

Abstract

Medical therapy plays a vital role in the neoadjuvant, adjuvant, and palliative management of patients with pancreatic cancer. The medical therapeutic options are largely limited to chemotherapy, and thus consideration for toxicity to balance with intended anticancer effect is requisite. The possible goals of therapy therefore need clear establishment at the outset. Various imaging modalities are an important part of the toolset needed to ascertain the baseline status of a cancer in terms of potential for resection, which will ultimately guide the treatments recommended and sequences of their use. These same imaging modalities remain critical to the assessment of treatment response over time. A considered understanding on how to use these imaging tools is important to ensure that a thorough and focused assessment of a patient’s cancer is achieved, and to tailor management to the individualized goals of the patient. In this chapter, the role of various imaging modalities will be discussed in the context of oncologic management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CA 19-9:

Carbohydrate antigen 19-9

CT:

Computed tomography

CTC:

Circulating tumor cells

ctDNA:

Circulating tumor DNA

ESPAC:

European Study Group for Pancreatic Cancer

EUS:

Endoscopic ultrasound

FOLFIRINOX:

5-fluorouracil/leucovorin, irinotecan, and oxaliplatin

mOS:

Median overall survival

PET:

Positron emission tomography

References

  1. Amanam I, Chung V. Targeted therapies for pancreatic cancer. Cancers (Basel). 2018;10:E36.

    Article  Google Scholar 

  2. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:2541–55.

    Article  Google Scholar 

  3. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, et al. Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:2654–68.

    Article  Google Scholar 

  4. Cancer stat facts: pancreatic cancer. SEER database. In: https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed 27 May 2019.

  5. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

    Article  CAS  Google Scholar 

  6. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival with nab-paclitaxel plus gemcitabine. N Engl J Med. 2012;369:1691–703.

    Article  Google Scholar 

  7. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. Lancet. 2016;387:545–57.

    Article  CAS  Google Scholar 

  8. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.

    Article  CAS  Google Scholar 

  9. Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol. 2008;26:LBA4504.

    Article  Google Scholar 

  10. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.

    Article  CAS  Google Scholar 

  11. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomized, phase 3 trial. Lancet. 2017;389:1011–24.

    Article  CAS  Google Scholar 

  12. Conroy T, Hammel P, Hebbar M, Abdelghani MB, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.

    Article  CAS  Google Scholar 

  13. Nab-paclitaxel and gemcitabine vs gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer (the APACT study). In: https://clinicaltrials.gov/ct2/show/NCT01964430. Accessed 10 Jun 2019.

  14. Celgene. Top-line results announced from the international Phase 3 study evaluating adjuvant therapy with ABRAXANE in combination with gemcitabine vs. gemcitabine alone for patients with surgically resected pancreatic cancer [press release] (12 Mar 2019) [cited Jun 10, 2019]. Available from: https://s22.q4cdn.com/728481125/files/doc_news/2019/03/ABRAXANE-Combo-release-Final-Approved2.pdf

  15. Goff SL, Chabot JA. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer. Cancer J. 2012;18:602–8.

    Article  CAS  Google Scholar 

  16. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

    Article  CAS  Google Scholar 

  17. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9.

    Article  CAS  Google Scholar 

  18. Kindler HL, Hammel P, Reni M, Van Cutsem E, Mercade RM, Hall MJ, et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: Phase III POLO trial. J Clin Oncol. 2019;37:suppl:abstr LBA4.

    Article  Google Scholar 

  19. Satoi S, Yamamoto H, Takai S, Tanigawa N, Komemushi A, Yanagimoto H, et al. Clinical impact of multidetector row computed tomography on patients with pancreatic cancer. Pancreas. 2007;34:175–9.

    Article  Google Scholar 

  20. Nordback I, Saaristo R, Piironen A, Sand J. Chest computed tomography in the staging of pancreatic and periampullary carcinoma. Scand J Gastroenterol. 2004;39:81–6.

    Article  CAS  Google Scholar 

  21. Motosugi U, Ichikawa T, Morisaka H, Sou H, Muhi A, Kimura K, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging. Radiology. 2011;260:446–53.

    Article  Google Scholar 

  22. Valls C, Andia E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, et al. Dual phase helical CT of pancreatic adenocarcinoma. Am J Roentgenol. 2002;178:821–6.

    Article  Google Scholar 

  23. Varadarajulu S, Wallace MB. Applications of endoscopic ultrasonography in pancreatic cancer. Cancer Control. 2004;11:15.

    Article  Google Scholar 

  24. Saftoiu A, Vilmann P. Role of endoscopy ultrasound in the diagnosis and staging of pancreatic cancer. J Clin Ultrasound. 2009;37:1.

    Article  Google Scholar 

  25. Fong ZV, Alvino DML, Fernandez Del Castillo C, Mehtsun WT, Pergolini I, Warshaw AL, et al. Reappraisal of staging laparoscopy for patients with pancreatic adenocarcinoma. Ann Sug Oncol. 2017;24:3203.

    Article  Google Scholar 

  26. Robinson SM, Wilson CH, Burt AD, MAnas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases. Ann Surg Oncol. 2012;19:4287–99.

    Article  Google Scholar 

  27. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended preoperative chemotherapy foes not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17:2870–6.

    Article  Google Scholar 

  28. NCCN. Pancreatic Adenocarcinoma. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 25 July 2019.

  29. Goonetilleke KS, Siriwadrena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–70.

    Article  CAS  Google Scholar 

  30. Saxena R. In Focus: circulating tumor cells. Available from: Pharmaceurticalintelligence.com. Accessed 18 May 2018.

  31. Varley K. Detecting ctDNA. Available from: uofuhealth.utah.edu. Accessed 18 May 2018.

  32. Liquid biopsy. Available from: healio.com. Accessed 18 May 2018.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brandon G. Smaglo .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Smaglo, B.G. (2021). Imaging Diagnostics in Pancreatic Cancer from the Perspective of an Oncologist. In: Anand, N., Darwin, P. (eds) Imaging Diagnostics in Pancreatic Cancer. Clinical Gastroenterology. Humana, Cham. https://doi.org/10.1007/978-3-030-69940-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-69940-6_6

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-69939-0

  • Online ISBN: 978-3-030-69940-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics